To navigate a field where "aging" is not a recognized disease, Rejuvenate Biomed targets sarcopenia, a specific, age-related muscle-wasting condition. This provides a clear regulatory path to market. Success in this indication generates data that validates their broader platform for healthy aging, effectively using a specific disease to pioneer an entirely new therapeutic category.
To pioneer treatments in the new field of aging, the company's strategy is to create new combinations from existing products with established human safety profiles. This adheres to a strict "do no harm" principle, significantly reducing the safety risk and regulatory uncertainty inherent in developing entirely new chemical entities for a preventative, long-term indication.
Beyond providing non-dilutive capital, the Flemish government's funding system (VLAIO) includes access to experts who actively challenge a startup's scientific proposals. This process forces strategic rigor and helps refine projects to be more translatable and robust. This built-in expert review is a key advantage of the Belgian biotech ecosystem, making companies smarter, not just richer.
To test its lead drug for muscle aging, Rejuvenate Biomed conducted a Phase 1 study where healthy volunteers wore a full leg cast for two weeks to induce acute sarcopenia. This innovative model allowed them to quickly and safely measure the drug's effect on muscle strength recovery in a highly controlled setting, de-risking the move into larger patient trials.
The company's drug discovery platform was built out of necessity to identify combination therapies for aging. Having proven its value internally, the strategic plan for the next 12-24 months includes making it commercially available through collaborations. This creates a new potential revenue stream and leverages an internal asset for external partnerships, diversifying the business model beyond its own pipeline.
To explain how a single therapy can affect multiple diseases, Ann Belien compares organs to countries and underlying biological mechanisms (like mitochondrial health) to languages. While countries are distinct, a shared language can connect many. This powerful analogy helps stakeholders understand how targeting a fundamental biological 'language' can impact many different organ-specific 'countries' or diseases.